Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulus Hit As Partner Sanofi Pulls Plug On Kidney Drug Study

Rare Kidney Diseases Proving Difficult For Both Companies

Executive Summary

Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.

You may also be interested in...



Sanofi Suffers Second Clinical Setback For Venglustat

The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.

Moderna Prepares To Enter The RSV Vaccine Fray

Its mRNA-based RSV vaccine challenger has a more convenient administration than GSK and Pfizer’s frontrunners, but may not compete on durability of protection.

Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes

Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel